MedTrace Logo

The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients

NCT04947345 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2021-07-01

No results posted yet for this study

Summary

This trial intends to evaluate Remimazolam Besylate's availability and safety compared with propofol.

Conditions

  • Analgesia
  • Postoperative Pain

Interventions

DRUG

Remimazolam Besylate

Remimazolam Besylate are used as sedatives for subjects in this arm.

DRUG

Propofol

Propofol are used as sedatives for subjects in this arm.

Sponsors & Collaborators

  • Yichang Humanwell Pharmaceutical Co., Ltd., China

    collaborator INDUSTRY

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-03-01
Completion
2022-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04947345 on ClinicalTrials.gov